Basics of genetic testing in Myeloproliferative neoplasms and understanding test reports

30 May 2020, Sunday


This video covers basics of genetic testing, clinical applications in Myeloproliferative Neoplasms and understanding test reports

AML Risk Stratification – Understanding Fragment Analysis and NGS panel test results

30 May 2020, Sunday


This video talks about Acute Myeloid Leukemia (AML) risk stratification, FLT3 testing in AML and understanding the test reports.

Inborn Errors of Metabolism

Part 1 – Inborn Errors of Metabolism – What a Clinician needs to know!

  8th May 2020, 4PM

Part 2 – Next Generation Sequencing (NGS) for diagnosis of Inborn Errors of Metabolism


12th May 2020, 4PM

Role of TP53 Gene in Hematolymphoid Malignancies and Multiple Myeloma

Date & Time: 22nd May, 2020; 4pm – 5pm

Mutations of the TP53 gene and dysregulation of the TP53 pathway are important in the pathogenesis of many human cancers, including leukemias, lymphomas and myelomas. Tumor suppressor p53 protein (cellular tumor antigen p53), is “the guardian of the genome,” preserves genome stability under cellular stress, and is involved in various processes of development, differentiation, aging, and disease.

Dysfunction of p53 in human cancers can result from deletion, mutations, and dysregulation of TP53 gene expression and other p53 related activities. These mechanisms provide multiple ways to inactivate the functions of the TP53 pathway. This opens up a wide spectrum of applications of TP53 gene testing for hematolymphoid malignancies as well as Multiple Myeloma.

Next Gen Sequencing for Next Gen Clinician: Difficult Codes Demystified!

Date & Time: 21st May, 3 pm

Next generation sequencing is slowly replacing the traditional technologies for the diagnosis of genetic disorders. Instead of gene-by-gene approach, large sets or panel of genes can now be analysed in a single test. The widespread application of NGS in research has led to its broad acceptance as a diagnostic tool, thereby replacing most of the other molecular diagnostic technologies.


Implementation of NGS technology into routine diagnostics requires strategic choices and specific guidelines and protocols to be followed. Clinical healthcare providers can be confident in explaining the NGS results to the patient when they understand the strengths and weaknesses of the bioinformatic analytics that generated the data for interpretation.

Utility and Best Practices in NIPT

Date & Time: 11th June 2020, 3pm

Speakers :

  1. Dr. Priya Kadam (Associate Director- Reproductive Genomics, MedGenome Labs )
  2. Dr. E Venkatswamy (Associate Director-Quality Assurance, MedGenome Labs)

Summary of the Talk

Non-invasive prenatal testing (NIPT) is one of the best methods of screening for aneuploidies in the fetus, prenatally. The technique is know to be highly reliable and accurate in aneuploidy detection. It has also seen increased adoption in India because of better understanding and increased awareness about the availability of the test.

This webinar will focus on the clinical utility of NIPT and look at some of recent discussion points including expanded screening. As an early laboratory adopter and with an experience of processing thousands of samples across platforms, best practices for a successful test will be discussed.

Covid-19 Testing – Yesterday, Today and Tomorrow

Time & Date: 12th June 2020 from 11:00am (IST) onwards

  1.  Smt K K Shailaja, Hon. Minister, Health and Social Welfare, Kerala State
  2.  Dr Shivkumar S Utture, President, Maharashtra Medical Council, Member of National Medical Commission (renowned General Physician)
  3. Dr Padmanabha Shenoy, Founder, CARE (renowned Immunologist)
  4. Dr Vedam Ramprasad, CEO, MedGenome, India 
  5. Mr Ranabir Sinha, Head-Key Accounts, Roche Diagnostics India
  6. Dr Anup R Warrier, Senior Consultant, Department of Infectious Diseases, Aster Medcity | Lead, Infectious Diseases & Hospital Infection Control Program, Aster DM Healthcare India Units   

Hear from the industry experts on their quest to find the best possible resolution not just for today but for tomorrow as well. Key areas to cover : Cutting edge technologies, Capacity building, Seroprevalence studies, Clinician supports, Pandemic management in future, etc. to address one of the most critical issues in managing a pandemic of the scale of COVID-19 in a country like India.

Registration is free and open to all. To register, please click

MedGenome invites you to a webinar on GenomeAsia Phase 3 – Creating a Resource to Understand the Genetics of Disease in India

Date and Time: 26th June, 5:30 pm IST

Speaker: Dr. Andrew Peterson (Chief Scientific Officer, MedGenome, USA)


Summary of the talk:

Population-scale genetic studies can allow disease risk to be predicted with resulting benefit for management of individual health risks and system-wide allocation of health care delivery resources while also identifying targets for drug discovery.